Please login to the form below

Not currently logged in
Email:
Password:

perianal fistulas

This page shows the latest perianal fistulas news and features for those working in and with pharma, biotech and healthcare.

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Will treat perianal fistulas in adult patients with Crohn’s disease. Takeda has chalked up a big win this week after receiving a European licence for Alofisel (darvadstrocel), marking the first ... Alofisel - previously Cx601 - is approved to treat

Latest news

  • Takeda offers €520m for stem cell firm TiGenix Takeda offers €520m for stem cell firm TiGenix

    Takeda’s bid comes shortly after TiGenix’ CX-601 (darvadstrocel), an allogeneic (donor) stem cell therapy for Crohn’s patients with perianal fistulas, was recommended for approval by the EU Committee ... Perianal fistulas are the most common type

  • CHMP backs Europe’s first allogeneic stem cell therapy CHMP backs Europe’s first allogeneic stem cell therapy

    Belgian biotech TiGenix and partner Takeda have had their stem cell therapy for perianal fistulas in Crohn’s disease patients recommended for approval in the EU. ... Perianal fistulas are the most common type, linking the bowel to the skin near the anus

  • TiGenix’s Crohn's fistulas treatment wins orphan drug status TiGenix’s Crohn's fistulas treatment wins orphan drug status

    The drug - currently known as Cx601 - could potentially treat ‘complex’ perianal fistulas in patients with Crohn’s disease who have had an inadequate response to at least one conventional or biologic ... It was found that a single dose of Cx601 was

  • TiGenix cell therapy for Crohn's fistulas shows long-term benefit TiGenix cell therapy for Crohn's fistulas shows long-term benefit

    Results of the phase III ADMIRE-CD trial show that a single administration of Cx601 - a suspension of allogeneic adipose-derived stem cells - was significantly more likely to heal perianal fistulas ... Perianal fistulas are the most common type, linking

  • An ethical division

    Approaching the market. Cellerix is developing expanded autologous adipose (fat)-derived stem cells for the potential treatment of complex perianal fistula, with and without Crohn's disease. ... In Europe in February 2007, a comparative, randomised,

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    for local administration for the treatment of complex perianal fistulas in patients with Crohn’s disease. ... Option exercise (2 options). 640. TiGenix/Takeda. Cx601, lead asset, allogeneic expanded adipose-derived stem cells (eASC) locally

  • Deal Watch July 2016 Deal Watch July 2016

    cells. The product has been submitted to the EMA following a phase III trial showing safety and efficacy of a single injection in the treatment of complex peri-anal fistulas, and ... Acquisition. 416. TiGenix/ Takeda. Cx601 - Stem cell treatment for

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
KVA

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....